Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo attack targets hard-to-treat KRAS G12C cancers

NCT ID NCT05358249

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug called JDQ443, which targets a specific cancer-driving mutation (KRAS G12C), in combination with other drugs (trametinib, ribociclib, or cetuximab). The trial enrolls about 74 people with advanced solid tumors (like lung or colorectal cancer) that have this mutation and have already tried standard treatments. The goal is to find safe doses and see if these combinations can shrink tumors or control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

JDQ443 (a KRAS G12C inhibitor) combined with trametinib, ribociclib, or cetuximab

What this could lead to

If successful, this could point toward new combination treatments that shrink or control advanced KRAS G12C cancers like lung and colorectal cancer.

What could go wrong

This is an early-phase trial (phase 1b/2) with only 74 participants, so results may not apply to all patients. Combinations may cause significant side effects or fail to improve outcomes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal carcinoma colorectal neoplasm lung cancer non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, NON-SMALL-CELL LUNG COLORECTAL CANCER COLORECTAL CARCINOMA COLORECTAL NEOPLASMS COLORECTAL TUMORS KRAS G12C MUTANT SOLID TUMORS NEOPLASMS, COLORECTAL NON SMALL CELL LUNG CARCINOMA NON-SMALL-CELL LUNG CANCER NONSMALL CELL LUNG CANCER

Contacts and locations

Locations

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • NYU School of Medicine

    New York, New York, 10015, United States

  • Novartis Investigative Site

    Leuven, 3000, Belgium

  • Novartis Investigative Site

    Bordeaux, 33076, France

  • Novartis Investigative Site

    Lyon, 69373, France

  • Novartis Investigative Site

    Freiburg im Breisgau, Baden-Wurttemberg, 79106, Germany

  • Novartis Investigative Site

    Milan, MI, 20162, Italy

  • Novartis Investigative Site

    Singapore, 168583, Singapore

  • Novartis Investigative Site

    Seoul, 03080, South Korea

  • Novartis Investigative Site

    Barcelona, 08036, Spain

  • Novartis Investigative Site

    Madrid, 28034, Spain

  • Novartis Investigative Site

    Madrid, 28050, Spain